KY
Roles
Therapeutic Areas
GeneDx Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Whole Exome Sequencing (XomeDx) | Rare Mendelian & Neurodevelopmental Disorders | Commercial |
| Whole Genome Sequencing | Rare Diseases & Unexplained Medical Complexity | Commercial |
| XomeAI | Variant Interpretation & Re-analysis | Commercial |
| Hereditary Cancer Panels | Hereditary Breast/Ovarian Cancer, Lynch Syndrome, etc. | Commercial |
| Prenatal & Carrier Screening | Inherited Conditions & Prenatal Anomalies | Commercial |
| Cardiogenetics Panels | Inherited Cardiomyopathies, Arrhythmias, Aortopathies | Commercial |
| SarcomaID | Solid Tumor Classification (Sarcoma) | Commercial |
Leadership Team at GeneDx Holdings
KS
Katherine Stueland
President, Chief Executive Officer, and Director
KF
Kevin Feeley
Chief Financial Officer
PK
Paul Kruszka
Chief Medical Officer
SL
Shenela Lakhani
Vice President, Medical Affairs & Clinical Genomics
JR
Jason Ryan
Executive Chairman of the Board
ES
Eric Schadt
Founder, former Chief Scientific Officer (Sema4)
MP
Michael Pellini
Board Director
SD
Scott D. Myers
Board Director
EC
Eli Casdin
Board Director
RA
Richard A. Scheller
Board Observer